Tocopherol-modified therapeutic drug compounds

Details Tocopherol-modified therapeutic drug compounds Tocopherol-modified therapeutic drug compounds

2007-05-29

2007-05-29

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S048000

Reexamination Certificate

active

10978222

ABSTRACT:
Tocopherol-modified therapeutic drug compounds; emulsion, microemulsion, and micelle formulations that include the compounds; methods for making the compounds and formulations; methods for administering the compounds and formulations; and methods for treating conditions using the compounds and formulations.

REFERENCES:
patent: 4665204 (1987-05-01), Wirth
patent: 5234695 (1993-08-01), Hobbs et al.
patent: 5606080 (1997-02-01), Ogata et al.
patent: 5610180 (1997-03-01), Fariss
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 5858398 (1999-01-01), Cho
patent: 5891469 (1999-04-01), Amselem
patent: 5917060 (1999-06-01), Rosenau et al.
patent: 5945409 (1999-08-01), Crandall
patent: 6045826 (2000-04-01), Borowy-Borowski et al.
patent: 6191172 (2001-02-01), Borowy-Borowski et al.
patent: 6319943 (2001-11-01), Joshi et al.
patent: 6387882 (2002-05-01), Ogata et al.
patent: 6417223 (2002-07-01), Sanders et al.
patent: 6458373 (2002-10-01), Lambert et al.
patent: 6479540 (2002-11-01), Constantinides et al.
patent: 6545125 (2003-04-01), Fujii
patent: 6576636 (2003-06-01), Webb et al.
patent: 6660286 (2003-12-01), Lambert et al.
patent: 6683194 (2004-01-01), Zhang et al.
patent: 6727280 (2004-04-01), Palepu et al.
patent: 6858227 (2005-02-01), Lal et al.
patent: 2002/0103254 (2002-08-01), Joshi-Hangal et al.
patent: 4423915 (1996-01-01), None
patent: 0 008 573 (1980-03-01), None
patent: 1 395 994 (1975-05-01), None
patent: 1 409 612 (1975-10-01), None
patent: WO 95/11039 (1995-04-01), None
patent: WO 95/31217 (1995-11-01), None
patent: WO 97/44026 (1997-11-01), None
patent: WO 97/44336 (1997-11-01), None
patent: WO 99/04787 (1999-02-01), None
patent: WO 00/71163 (2000-11-01), None
patent: WO 02/076970 (2002-10-01), None
patent: WO 02/083067 (2002-10-01), None
Nielsen, et al., “The effect of alpha-tocopherol on the in vitro solubilisation of lipophilic drugs” Internation J. of Pharmaceutics 222, (2001) 217-224.
Constantinides, et al., “Tocol emulsions for drug solubilization and parenteral delivery”, Advanced Drug Delivery Reviews 56, (2204), 1243-1255.
Cancer Classification (available at: http://training.seer.cancer.gov/module—cancer—disease/unit3—categories2—by—histology.html).
Grever et al., The National Cancer Institute: Cancer Drug Discovery and Development Program, Seminars in Oncology, 19:6 622-638 (1992).
product description for HTB-177 (available at http://www.atcc.org/common/catalog
umSearch
umResults.cfm?atccNum=HTB-177).
ATCC “product description Cell culture HTB-161” (2007).
Clontech laboratories, Inc. “Product description: cancer cell lines” (2007).
Edeas, M.A., et al., “Protective Effects of the Lipophilic Redox Conjugate Tocopheryl Succinyl-Ethyl Ferulate on HIV Replication,”FEBS Letters 418:15-18, 1997.
Lalloo, A.K., et al., “Membrane Transport of Camptothecin: Facilitation by Human P-Glycoprotein (ABCB1) and Multidrug Resistance Protein 2 (ABCC2),”Biomedcentral.com,<http://www/biomedcentral.com/1741-7015/2/16> [retrieved Oct. 28, 2004]; also availableBMC Medicine 2:16, 2004.
Li, C., et al., “Antitumor Activity of Poly(L-Glutamic Acid)-Paclitaxel on Syngeneic and Xenografted Tumors,”Clinical Cancer Research 5:891-897, Apr. 1999.
Qasem, J.G., et al., Kinetics of Paclitaxel 2'-N-methylpyridinium Mesylate Decomposition,AAPS PharmSciTech 4(2):1-8; also available www.pharmscitech.org.
Rigas, J.R., “Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review,”The Oncologist,<http://thoncologist.alphamedpress.org/cgi/content/full/9/suppl—2/16> [retrieved Oct. 28, 2004]; also availableThe Oncologist 9, Suppl. 2, 16-23, Jun. 2, 2004.
Ansel, S.M., et al., Synthesis and Formulation of a Lipophilic Prodrug of Paclitaxel for Liposomal Delivery,Abstracts of Papers American Chemical Society 212(1-2), p. MEDI 48, and 212th American Chemical Society National Meeting, Orlando, Florida, Aug. 25-29, 1996 (abstract only).
Dallavalle, S., et al., “Perspectives in Camptothecin Development,”Expert Opinion on Therapeutic Patents 12(6):837-844, 2002.
Liu, X., et al., “A Versatile Prodrug Approach for Liposomal Core-Loading of Water-Insoluble Camptothecin Anticancer Drugs,”J. Am. Chem. Soc. 124(26):7650-7651, 2002.
Lundberg, B.B., et al., “A Lipophilic Paclitaxel Derivative Incorporated in a Lipid Emulsion for Parenteral Administration,”Journal of Controlled Release 86(1):93-100, Jan. 9, 2003.

Affiliated with

Also associated with

Rating

Tocopherol-modified therapeutic drug compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tocopherol-modified therapeutic drug compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tocopherol-modified therapeutic drug compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3792450